Foundation University Islamabad
fui.edu.pkLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
221
Active
102
Phase 3
0
Total enrollment
10,226
Pipeline matrix
Showing 8 of 8 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Topical 30% metformin cream | — | — | — | — | — | 2 | |
| Tacrolimus | — | — | — | — | — | 1 | |
| Crisaborole 2% Top Oint | — | — | — | — | — | 1 | |
| topical 3% tranexamic acid solution | — | — | — | — | — | 1 | |
| Kligman's Regimen | — | — | — | — | — | 1 | |
| Botox injection into extraocular muscles | — | — | — | — | — | 1 | |
| Study for the correlation of SNPs with efficacy and toxicity of Leflunomide in RA patients | — | — | — | — | — | 1 | |
| Pharmacological therapy | — | — | — | — | — | 1 |
Next readouts
- 2025-01-01
- 2026-06-30
- 2026-11-01
- 2026-12-01
- 2026-12-01
- 2030-08-30
Top conditions
- Low Back Pain16
- Balance12
- Neck Pain11
- Stroke7
- Adhesive Capsulitis6
- Knee Osteoarthritis6
- Postural Balance5
- Piriformis Syndrome5
Frequently asked questions about Foundation University Islamabad
- How many clinical trials does Foundation University Islamabad have on ClinicalTrials.gov?
- Foundation University Islamabad is listed as the lead sponsor on 221 clinical trials in ClinicalTrials.gov, 102 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Foundation University Islamabad's trials are in Phase 3?
- 0 of Foundation University Islamabad's trials are in Phase 3, spread across 8 active drug programs.
- What therapeutic areas does Foundation University Islamabad focus on?
- Foundation University Islamabad's most-studied conditions on ClinicalTrials.gov are Low Back Pain, Balance, Neck Pain, Stroke, Adhesive Capsulitis.
- When are Foundation University Islamabad's next clinical trial readouts?
- Foundation University Islamabad has 6 upcoming primary-completion readouts tracked here; the soonest is “Additive Effects of Alternative Nostril Breathing with Pharmacological Management on Dyspnea and Control Pause in Patients with Bronchial Asthma”, expected around 2025-01-01.